Evidence map›Paper›PMID 33674671›Full record

Trial reportScientific reports2021

Whole genome methylation and transcriptome analyses to identify risk for cerebral palsy (CP) in extremely low gestational age neonates (ELGAN).

An N Massaro, Theo K Bammler, James W MacDonald, Krystle M Perez, Bryan Comstock, Sandra E Juul

Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. An Emerging Role for Epigenetics in Cerebral Palsy.Journal of personalized medicine · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

An N MassaroDepartment of Neonatology, Pediatrics - Division of Neonatology, Children's National Health Systems, The George Washington University School of Medicine, 111 Michigan Avenue, NW, Washington, DC, 20010, USA. anguyenm@cnmc.org.
Theo K BammlerDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA.
James W MacDonaldDepartment of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA.
Krystle M PerezPediatrics - Division of Neonatology, University of Washington, Seattle, WA, USA.
Bryan ComstockDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
Sandra E JuulPediatrics - Division of Neonatology, University of Washington, Seattle, WA, USA.
University of Washington · USGeorge Washington University · US

Funding

Preterm Epo Neuroprotection Trial (PENUT Trial) CCCU01NS077953 · NINDS · UNIVERSITY OF WASHINGTON · PI JUUL, SANDRA E · 2013 to 2018
$10.7M
NINDS NIH HHS U01 NS077953
6 · The paper itself

Abstract

Preterm birth remains the leading identifiable risk factor for cerebral palsy (CP), a devastating form of motor impairment due to developmental brain injury occurring around the time of birth. We performed genome wide methylation and whole transcriptome analyses to elucidate the early pathogenesis of CP in extremely low gestational age neonates (ELGANs). We evaluated peripheral blood cell specimens collected during a randomized trial of erythropoietin for neuroprotection in the ELGAN (PENUT Trial, NCT# 01378273). DNA methylation data were generated from 94 PENUT subjects (n = 47 CP vs. n = 47 Control) on day 1 and 14 of life. Gene expression data were generated from a subset of 56 subjects. Only one differentially methylated region was identified for the day 1 to 14 change between CP versus no CP, without evidence for differential gene expression of the associated gene RNA Pseudouridine Synthase Domain Containing 2. iPathwayGuide meta-analyses identified a relevant upregulation of JAK1 expression in the setting of decreased methylation that was observed in control subjects but not CP subjects. Evaluation of whole transcriptome data identified several top pathways of potential clinical relevance including thermogenesis, ferroptossis, ribosomal activity and other neurodegenerative conditions that differentiated CP from controls.

Indexed as

Infant, Extremely PrematureCerebral PalsyDNA MethylationFemaleHumansMalePremature BirthTranscriptome

Identifiers

PMID33674671
PMCPMC7935929
OpenAlexW3133573211

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.